REG - Renalytix PLC - Result of AGM

RenalytixAnnouncement

Tue 11:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251209:nRSI8519Ka&default-theme=true

RNS Number : 8519K  Renalytix PLC  09 December 2025

Renalytix plc

("Renalytix" or the "Company")

 

Result of AGM

 

LONDON and NEW YORK, 9 December 2025 - Renalytix plc (LSE: RENX) (OTCQB:
RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the
only FDA-approved and Medicare reimbursed prognostic test to support
early-stage risk assessment in chronic kidney disease,  announces that at
the Annual General Meeting ("AGM") held earlier today, all resolutions were
duly passed.

 

The results of the AGM are detailed below:

 

                                                                    For           % voted in favour    Against     % voted against    Withheld
 Ordinary resolutions
 1            Receive and adopt the UK 2025 Annual Report           196,930,280  99.7                 587,105     0.3                20,878
 2            Approve Directors' Remuneration Report                195,421,372  98.9                 2,073,488   1.1                43,403
 3            Re-appointment of Christopher Mills as a Director     178,267,303  90.3                 19,130,050  9.7                140,910
 4            Re-appointment of James McCullough as a Director      194,129,345  98.3                 3,268,008   1.7                140,910
 5            Re-appointment of Fergus Fleming as a Director        195,999,932  99.3                 1,386,266   0.7                152,065
 6            Re-appointment of Erik Lium as a Director             177,457,676  89.9                 19,928,522  10.1               152,065
 7            Re-appointment of Julian Baines as a Director         195,385,929  99.3                 1,378,854   0.7                773,480
 8            Re-appointment of Robert Naylor as a Director         196,012,978  99.3                 1,373,220   0.7                152,065
 9            Reappoint PKF Littlejohn LLP as Auditors              196,188,779  99.3                 1,276,304   0.7                73,180
 10           Authorise Board to determine auditors' remuneration   196,927,685  99.7                 555,598     0.3                54,980
 11           Authorise the Issue of Equity                         195,214,647  98.9                 2,147,594   1.1                176,022

 Special resolutions
 12           Authorise Issue of Equity without Pre-emptive Rights  193,317,050  97.9                 4,042,090   2.1                179,123
 13           Authorise Market Purchase of Ordinary Shares          195,114,033  98.8                 2,381,796   1.2                18,678

 

 

For further information, please contact:

 

 Renalytix plc                                         www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                                 Via Walbrook PR

 SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)             Tel: +44 (0)20 3470 0470
 Jeff Keating / David Hignell (Corporate Finance)

 Vadim Alexandre (Corporate Broking)

 Oberon Capital (Joint Broker)                         Tel: +44 (0)20 3179 5300
 Mike Seabrook / Nick Lovering

 Walbrook PR Limited        Tel: +44 (0)20 7933 8780 or renalytix@walbrookpr.com
                            (mailto:renalytix@walbrookpr.com)
 Paul McManus / Alice Woodings                         Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

About Renalytix (www.renalytix.com)

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in
vitro diagnostics company, focused on optimizing clinical management of kidney
disease to drive improved patient outcomes. Renalytix has received FDA
approval and Medicare reimbursement for kidneyintelX.dkd which is now offered
commercially in the United States.

 

Unrecognized and uncontrolled kidney disease remains one of the largest
barriers to controlling cost and suffering in the United States and the United
Kingdom's medical system, affecting approximately 15 million and 8 million
people, respectively. After five years of development and clinical validation,
kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic
tool capable of understanding a patient's risk with kidney disease early where
treatment has maximal effect. kidneyintelX.dkd is now being deployed across
large physician group practices and health systems in select regions of the
United States.

 

The over 15,000 patients that have been tested by kidneyintelX.dkd have
produced a substantial body of real-world performance data. In patient
populations where kidneyintelX.dkd has been deployed, a demonstrated and
significant increase in diagnosis, prognosis, and treatment rates have been
recorded. kidneyintelX.dkd now has full reimbursement established by Medicare,
the largest insurance payer in the United States, at $950 per reportable
result. kidneyintelX.dkd is also recommended for use in the international
chronic kidney disease clinical guidelines (KDIGO).

 

KidneyIntelX is based on technology developed by Mount Sinai faculty and
licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and
equity owners in the Company. In addition, the Icahn School of Medicine at
Mount Sinai has equity ownership in Renalytix. For information about the
kidneyintelX,dkd test, visit kidneyintelx.com (http://kidneyintelx.com/) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGBGBDDUUGDGUC



            Copyright 2019 Regulatory News Service, all rights reserved